Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents

Anesthesiology. 2008 Oct;109(4):596-604. doi: 10.1097/ALN.0b013e318186de1c.


Background: The American College of Cardiology released a scientific advisory that included a recommendation to delay elective of noncardiac surgery (NCS) for 1 yr after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES).

Methods: This single-center, retrospective study examined the risk for complications of NCS performed within 2 yr after DES placement and examined whether this risk changed based on the time between procedures. The primary endpoint was major adverse cardiac events (MACEs) during the hospitalization for NCS. Bleeding events were analyzed as a secondary endpoint.

Results: From April 22, 2003, to December 31, 2006, a total of 520 patients underwent NCS within 2 yr after PCI with a DES at Mayo Clinic. The majority, 84%, of the DES placed were Cypher stents. The frequency of MACE was not found to be significantly associated with the time between PCI and NCS (rate of MACEs 6.4, 5.7, 5.9, and 3.3% at 0-90, 91-180, 181-365, and 366-730 days after PCI with DES, respectively; P = 0.727 for comparison across groups). Characteristics found to be associated with MACEs in univariate analysis were advanced age (P = 0.031), emergent NCS (P = 0.006), shock at time of PCI (P = 0.035), previous history of myocardial infarction (P = 0.046), and continuation of a thienopyridine (ticlopidine or clopidogrel) into the preoperative period (P = 0.040). The rate of transfusion did not seem to be associated with antiplatelet therapy use.

Conclusions: The risk of MACEs with NCS after DES placement was not significantly associated with time from stenting to surgery, but observed rates of MACEs were lowest after 1 yr.

MeSH terms

  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Blood Loss, Surgical
  • Blood Transfusion
  • Drug-Eluting Stents / adverse effects*
  • Female
  • Humans
  • Male
  • Metals
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Risk Factors
  • Surgical Procedures, Operative / adverse effects*
  • Time Factors


  • Metals
  • Platelet Aggregation Inhibitors